This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2015 by Stephan Stilgenbauer, University of Ulm.
Recruitment status was:  Active, not recruiting
Sponsor:
Collaborators:
IMSE, TU Munich (Biometry)
WiSP Wissenschaftlicher Service Pharma GmbH
German CLL Study Group
Information provided by (Responsible Party):
Stephan Stilgenbauer, University of Ulm
ClinicalTrials.gov Identifier:
NCT01392079
First received: June 28, 2011
Last updated: May 27, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)